Latest $10 million payment from Celgene triggered by development of spray drying technology that advances commercial-scale manufacturing (Image: Sutro Biopharma).
First approved therapy for XLH in the US and only treatment targeting the underlying cause of this rare, hereditary, lifelong disease.
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.
| Website: | www.ultragenyx.com |
| Email: | dkeatley@ultragenyx.com |
| Main Phone: | +1 415 483-8800 |
| Address: | 60 Leveroni Court |
| State: | CA |
| City / Town: | Novato |
| Country: | US |
| Postal Code: | 94949 |
| Exchange: | NGS |
| CEO: | Emil D. Kakkis |
| Employees: | 893 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Latest $10 million payment from Celgene triggered by development of spray drying technology that advances commercial-scale manufacturing (Image: Sutro Biopharma).
First approved therapy for XLH in the US and only treatment targeting the underlying cause of this rare, hereditary, lifelong disease.
Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He
Results for Monday, March 10 ? Standard & Poor’s 500: -0.05 to 1,877.17 ? Dow Jones Industrial Average: -0.21 percent to
Ultragenyx Pharmaceutical ($RARE) is a biopharmaceutical company that focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no
The full IPO calendar from IPOpremium.com is here. Ranked in order of largest first, the six IPOs are: (1) Based in Denver, CO, Intrawest Resort Holdings ($SNOW) scheduled a $250 million IPO on
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
